臺灣博碩士論文加值系統

使用塗藥植入材作為癌症藥物標靶傳遞的概念是生物植入材上的新興課題。鎂合金雖不具良好耐腐蝕性，但卻有機會成為生物可降解植入物的一個選項。本研究藉調變不同參數將氧化鋯(ZrO2)與氫氧基磷灰石(HAp)以電化學方法沉積至純鎂基材上，並進行熱退火處理。動態極化試驗顯示經過最好的沉積參數處理後能使鎂基材在37 °C下磷酸緩衝溶液的腐蝕電流密度59.4下降至1.88 μA/cm2，以X光繞射儀(XRD)鑑定其結晶構造、場發射式電子顯微鏡(FESEM)觀察其表面形貌、多功能聚焦離子束系統(FIB)檢視鍍層的厚度與剖面結構。此外，且企圖將紫杉醇(PTX)沉積至前述基材上，並以傅立葉紅外線光譜儀(FTIR)分析特徵化學鍵結吸收光譜值，藉以評估紫杉醇承載趨勢。

The concept of using drug-loaded implant in targeted drug delivery as cancer therapy is a new topic of bio-implants. Though pure magnesium used to construct an absorbable bio-implant could be another candidate, the poor corrosion resistance is relatively a serious impediment for wider applications. In this study, the coatings of zirconia (ZrO2) bottom layer and hydroxyapatite (HAp) top layer are carried out on pure magnesium specimens by tuning parameters of electrochemical deposition and subsequent annealing, leading to the corrosion current density reduced from 59.4 to 1.88 μA/cm2 derived by potentialdynamic polarization tests in phosphate buffered saline (PBS) at 37 °C. The corrosion resistance composite layer is analyzed by grazing incidence X-Ray differactometry (XRD-GID) for crystal structure, field-emission scanning electron microscope (FESEM) to observe surface morphology and focused ion beam system (FIB) for cross section observation. Furthermore, paclitaxel is electrolytically deposited on post HAp/ZrO2 coated specimens, using Fourier transform infrared spectroscopy (FTIR) to observe the absorbance of chemical bonding of paclitaxel for estimating the tendency of drug loading.

摘要 i
Abstract ii
Contents iii
Table Contents iv
Figure Contents v
1. Introduction 1
2. Materials and methods 5
2-1 Materials 5
2-2 Cathodic polarization tests and deposition 5
2-3 Coating characterization 6
2-4 Degradation evaluation 6
2-4 Paclitaxel characterization 7
3. Results and discussion 8
3-1 Polarization 8
3-2 Coating characterization 12
3-2.1 X-Ray diffraction 12
3-2.2 FESEM 14
3-2.3 Cross-section observations by focused ion beam (FIB) system 21
3-3 Corrosion Evaluation 25
3-4 FTIR 31
4. Summary and Conclusions 34
5. References 35

1.S. Saito, New horizon of bioabsorbable stent, Catheterization and Cardiovascular Interventions, 66 (2005) 595-596.
2.R. Zeng, W. Dietzel, F. Witte, N. Hort, C. Blawert, Progress and challenge for magnesium alloys as biomaterials, Advanced Engineering Materials, 10 (2008) B3-B14.
3.M.P. Staiger, A.M. Pietak, J. Huadmai, G. Dias, Magnesium and its alloys as orthopedic biomaterials: a review, Biomaterials, 27 (2006) 1728-1734.
4.H. Waizy, J.-M. Seitz, J. Reifenrath, A. Weizbauer, F.-W. Bach, A. Meyer-Lindenberg, B. Denkena, H. Windhagen, Biodegradable magnesium implants for orthopedic applications, Journal of Materials Science, 48 (2013) 39-50.
5.G. Song, S. Song, A possible biodegradable magnesium implant material, Advanced Engineering Materials, 9 (2007) 298-302
6.https://www.biotronik.com/en-za/newsroom/press-releases/press-release-magmaris-ce-mark-june15-en
7.M. J. Wang, S. C. Chao, S. K. Yen, Electrolytic calcium phosphate/zirconia composite coating on AZ91D magnesium alloy for enhancing corrosion resistance and bioactivity, Corrosion Science 104 (2016) 47–60.
8.M. J. Wang, C. F. Li, S. K. Yen, Electrolytic MgO/ZrO2 duplex-layer coating on AZ91D magnesium alloy for corrosion resistance, Corrosion Science 76 (2013) 142–153.
9.N. Cases, Macrophagic myofasciitis associated with vaccine-derived aluminium, The Medical Journal of Australia, 183 (2005) 145-146.
10.P. C. Ferreira, K.d.A. Piai, A.M.M. Takayanagui, S.I. Segura-Muñoz, Aluminum as a risk factor for Alzheimer's disease, Revista latino-americana de enfermagem, 16 (2008) 151-157.
11.L. Brannon-Peppas, J. O. Blanchette, Nanoparticle and targeted systems for cancer therapy, Advanced drug delivery reviews, 64 (2012) 206–212.
12.S. S. Feng, S. Chienc, Chemotherapeutic engineering: application and further development of chemical engineering principles for chemotherapy of cancer and other diseases , Chemical Engineering Science, 58 (2003) 4087–4114.
13."Paclitaxel". The American Society of Health-System Pharmacists. Retrieved May 11, (2015).
14.S. B. Horwitz, Taxol (paclitaxel): mechanisms of action, Annals of Oncology, 5 (1994) S3-6.
15.K.L. Hennenfent, R. Govindan, Novel formulations of taxanes: a review. Old wine in a new bottle? Annals of oncology, 17 (2006) 735-749.
16.K. Singla, A. Garg, D. Aggarwal, Paclitaxel and its formulations, International Journal of Pharmaceutics, 235 (2002) 179–192.
17.H. Gelderblom, J. Verweij, K. Nooter, A. Sparreboom, Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation, European Journal of Cancer, 37 (2001) 1590–1598.
18.U.S. Food and Drug Administration, TAXUS™ Express 2™ Paclitaxel-Eluting Coronary Stent System (Monorail and Over-the-Wire) - P030025, Updated 2004 http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cftopic/pma/pma.cfm?num=p0 30025
19.R. Jabara, N. Chronos, D. Conway, W. Molema, K. Robinson, Evaluation of a Novel Slow-Release Paclitaxel-Eluting Stent With a Bioabsorbable Polymeric Surface Coating, JACC: Cardiovascular Interventions, 1 (2008) 81–87.
20.W. Heldman, L. Cheng, G. M. Jenkins, P. F. Heller, D. W. Kim, M. Ware Jr, C. Nater, R. H. Hruban, B. Rezai, B. S. Abella, K. E. Bunge, J. L. Kinsella, S. J. Sollott, E. G. Lakatta, J. A. Brinker, W. L. Hunter, J. P. Froehlich, Paclitaxel Stent Coating Inhibits Neointimal Hyperplasia at 4 Weeks in a Porcine Model of Coronary Restenosis, Circulation, 103 (2001) 2289-2295.
21.Y. L. Lai, S. B. Lai, S. K. Yen, Paclitaxel/hydroxyapatite composite coatings on titanium alloy for biomedical applications, Materials Science and Engineering C 79 (2017) 622–628.
22.K. Watanabe, Y. Nishio, R. Makiura, A. Nakahira, C. Kojima, Paclitaxel-loaded hydroxyapatite/collagen hybrid gels as drug delivery systems for metastatic cancer cells, International Journal of Pharmaceutics, 446 (2013) 81–86.
23.T. Abe, M. Sakane, T. Ikoma, M. Kobayashi, S. Nakamura, N. Ochiai, Intraosseous delivery of paclitaxel-loaded hydroxyapatite alginate composite beads delaying paralysis caused by metastatic spine cancer in rats, Journal of Neurosurgery: Spine, 9 ( 2008)502-510.
24.G. D. Venkatasubbu, S. Ramasamy, G.S. Avadhani, V. Ramakrishnan, J. Kumar, Surface modification and paclitaxel drug delivery of folic acid modified polyethylene glycol functionalized hydroxyapatite nanoparticles, Powder Technology, 235 (2013) 437–442.
25.R. Ambat, N.N. Aung, W. Zhou, Studies on the influence of chloride ion and pH on the corrosion and electrochemical behaviour of AZ91D magnesium alloy, Journal of applied electrochemistry, 30 (2000) 865-874.
26.N. Hara, Y. Kobayashi, D. Kagaya, N. Akao, Formation and breakdown of surface films on magnesium and its alloys in aqueous solutions, Corrosion Science, 49 (2007) 166-175.
27.S.K. Yen, Characterization of electrolytic ZrO2 coating on AISI 316L stainless steel, Journal of The Electrochemical Society, 146 (1999) 1392-1396.
28.S. Pezzatini, R. Solito, L. Morbidelli, S. Lamponi, E. Boanini, A. Bigi, M. Ziche, The effect of hydroxyapatite nanocrystals on microvascular endothelial cell viability and functions, Journal of Biomedical Materials Research Part A, 76 (2006) 656-663.
29.A. G102-89, Standard practice for calculation of corrosion rates and related information from electrochemical measurements, ASTM, Philadelphia, PA, (2010).
30.J. Vormann, Mol. Aspects Med. 24 (2003) 27.
31.https://en.wikipedia.org/wiki/Hypermagnesemia
32.https://en.wikipedia.org/wiki/Paclitaxel
33.E. Süleymanoglu, The use of infrared spectroscopy for following drug-membrane interactions: probing paclitaxel (taxol)-cell phospholipid surface recognition, Rev Electron Biomed / Electron J Biomed, 3 (2009) 19-35.